Homozygous familial hypercholesterolemia (HoFH) is a genetic condition caused by mutations in the LDLR gene and characterized by severe hypercholesterolemia and premature cardiovascular disease. Repair Biotechnologies Inc. has developed REP-0003, a therapeutic based on the Cholesterol Degrading Platform (CDP) that degrades excessive intracellular free cholesterol into a non-toxic and excretable catabolite to safely reverse cholesterol-rich vulnerable plaque.
Heart failure with preserved ejection fraction (HFpEF) is a complex disease with limited therapeutic options. Protein histone deacetylase 6 (HDAC6) is known to be involved in several biological processes, such as autophagy or inflammation, among others, but its impact on HFpEF has not been well evaluated to date.
At first glance, the results of the CLOSURE-AF study would seem to spell doom for left atrial appendage closure devices for patients at risk of stroke, but there is some noise in the signal, including that the devices used in the study no longer represent the state of the med-tech art.
Patients and their doctors are no fans of long-term use of direct oral anticoagulants (DOACs) after ablation treatment for atrial fibrillation, but three-year data from the OCEAN trial suggests that some patients may not need these DOACs after all, an outcome that qualifies as a crowd-pleaser for all but the makers of these pharmaceutical agents.
Researchers from Monte Rosa Therapeutics Inc. reported preclinical efficacy data on MRT-8102, a selective NEK7 molecular glue degrader, designed to treat inflammatory diseases.
Shares of Mountain View, Calif.-based Heartflow Inc. have oscillated significantly over the past three months, but the results of a study of the company’s plaque staging system have breathed new life into the company’s shares, boosting them by 7% in Nov. 10 trading.
Kestra Medical Inc. seems to have put itself in a position to take a bite out of the market for wearable defibrillators with the results of the ASSURE WCD study, which enrolled more than 21,600 patients. The study, whose results were reported on at the American Heart Association annual meeting in New Orleans, demonstrated that Kestra’s unit delivered an inappropriate shock rate of only 0.0065 per patient per month, an outcome that analysts at Wells Fargo said will allow Kestra to close the gap on competitors such as Zoll Medical.
Data from a preclinical study assessing Mission Therapeutics Ltd.’s clinical-stage USP30 inhibitor MTX-652, for the prevention of transverse aortic constriction (TAC)-induced cardiac hypertrophy and remodeling, were recently presented.
Recent findings have unveiled that 15-HETE is the endogenous agonist for G protein-coupled receptor 39 (GPR39) in vascular smooth cells, so researchers hypothesized that GPR39 could work as a therapeutic target in pulmonary arterial hypertension and its deletion might prevent the development of the disease.
Potent siRNAs against B4GALT1 were designed in silico and screened in vitro (Huh7 cells, primary mouse, human hepatocytes) as well as in vivo (C57BL/6 mice) for the selection of a lead Galomic siRNA.
RSS
